DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

NCT03356080 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Decitabine
DRUG: Cytarabine
DRUG: All-transretinoic acid
DRUG: G-CSF

Sponsor

Shanghai Tong Ren Hospital